Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

This study tests a combination treatment of pembrolizumab (immunotherapy) with carboplatin and paclitaxel (standard chemotherapy) given before surgery in patients with small, early-stage triple-negative breast cancer. The goal is to see if this combination can shrink the tumor before it is removed. **You may be eligible if...** - You have been diagnosed with early-stage triple-negative breast cancer (meaning hormone receptor-negative and HER2-negative) - Your tumor is in the T1b or T1c stage (roughly 6mm to 2cm) - You have not yet received any treatment for this breast cancer - Your general health is adequate for chemotherapy **You may NOT be eligible if...** - Your cancer is hormone receptor-positive and your doctor recommends hormonal therapy - Your cancer has spread to lymph nodes or elsewhere in the body - You have active autoimmune disease or other serious medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.